Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alkaloid AD SkopjeXMAE:ALK 100 EBITDA Margin % is 9.21% as of Jun. 2026, which is 17% below its 10-year median of 11.08. GuruFocus rates XMAE:ALK with a GF Score™ of 100/100 and a GF Value™ of MKD26,949.24 (Modestly Undervalued). Among 958 Drug Manufacturers companies, Alkaloid AD Skopje ranks worse than 53.97% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Alkaloid AD Skopje's EBITDA for the
three
months ended in Jun. 2026 was MKD469 Mil. Alkaloid AD Skopje's Revenue for the
three
months ended in Jun. 2026 was MKD5,090 Mil. Therefore, Alkaloid AD Skopje's EBITDA margin for the quarter that ended in Jun. 2026 was 9.21%.
Alkaloid AD Skopje (XMAE:ALK) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Alkaloid AD Skopje EBITDA Margin % Related Terms
Alkaloid AD Skopje EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Alkaloid AD Skopje's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAE:ALK vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alkaloid AD Skopje's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alkaloid AD Skopje EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alkaloid AD Skopje's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Alkaloid AD Skopje's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alkaloid AD Skopje (XMAE:ALK) has a EBITDA Margin % of 9.21% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Alkaloid AD Skopje and its competitors. This is 17% below median its historical median of 11.08. Over the past decade, Alkaloid AD Skopje's EBITDA Margin % has ranged from 10.06 to 17.21. According to the industry distribution chart, Alkaloid AD Skopje ranks #517 out of 958 companies in the Drug Manufacturers industry, placing it in the top 54%.
Is Alkaloid AD Skopje's EBITDA Margin % too high?
Alkaloid AD Skopje's current EBITDA Margin % of 9.21% is 17% below median its 10-year median of 11.08. Over the past 10 years, this metric has ranged from a low of 10.06 to a high of 17.21. The Drug Manufacturers industry median EBITDA Margin % is 12.11. Alkaloid AD Skopje's value of 9.21% is 23.9% below this industry median. Based on the distribution chart, Alkaloid AD Skopje ranks #517 out of 958 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Alkaloid AD Skopje has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alkaloid AD Skopje's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Alkaloid AD Skopje ranks #517 out of 958 companies for EBITDA Margin %. This places Alkaloid AD Skopje in the lower half of its industry. The industry median EBITDA Margin % is 12.11. Alkaloid AD Skopje's value of 9.21% is 23.9% below this benchmark. Historically, Alkaloid AD Skopje's own EBITDA Margin % has ranged from 10.06 to 17.21 over the past decade. While the company's 10-year median is 11.08 vs. the industry median of 12.11, Alkaloid AD Skopje has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.11, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alkaloid AD Skopje's current EBITDA Margin % of 9.21% is 23.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Alkaloid AD Skopje and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alkaloid AD Skopje's current EBITDA Margin % is 9.21%, which is 17% below median its own 10-year median of 11.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alkaloid AD Skopje stock overvalued right now?
Based on GuruFocus' analysis, Alkaloid AD Skopje (XMAE:ALK) is currently considered Modestly Undervalued. The stock's GF Value™ is MKD26,949.24, compared to a current price of MKD23,000.00 — trading 14.7% below its estimated fair value. The current EBITDA Margin % is 9.21%, which is 17% below median its 10-year median of 11.08 and 23.9% below the Drug Manufacturers industry median of 12.11. Alkaloid AD Skopje's overall GF Score™ is 100/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Alkaloid AD Skopje (XMAE:ALK), the current EBITDA Margin % is 9.21% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alkaloid AD Skopje (XMAE:ALK) Overvalued in 2026?
Based on GuruFocus' analysis, Alkaloid AD Skopje stock appears to be undervalued.
The current stock price of MKD23,000.00 is trading 14.7% below its estimated GF Value™ of MKD26,949.24.
GuruFocus considers Alkaloid AD Skopje to be Modestly Undervalued.
Key valuation signals for XMAE:ALK:
EBITDA Margin %: 9.21% (17% below median its 10-year median of 11.08)
GF Value™: MKD26,949.24 vs. price of MKD23,000.00 (14.7% below fair value)
Industry Position: 23.9% below the Drug Manufacturers median (#517 of 958)
No single metric tells the full story. See the XMAE:ALK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alkaloid AD Skopje is engaged in producing and selling pharmaceutical, chemical and cosmetic products, as well as goods from the herbal origin. Its segments are Pharmaceuticals, Chemicals, Cosmetics and Botanicals. It derives maximum revenue from Pharmaceuticals products segment.
100GF Score
Get the complete analysis for XMAE:ALK
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAE:ALK has been successfully added to your 
